Newsletter registration

By using our website, you are agreeing to cookies being stored and Google Analytics being used on your device in order to offer the best possible service. You can find more information on thishere.
Austria.
Dynamic Business Location.

Hookipa: EUR 50 million for immunotherapy against cancer

© Hookipa Biotech

A vaccination against the Cytomegalovirus ("CMV"), which is a herpesvirus, should be tested on patients undergoing organ transplants. In addition, immunization therapy is to be tested on patients with head and neck squamous cell carcinoma. Founded in 2011, the company develops active immunotherapies against cancer and infectious diseases. The new investors include a blue-chip U.S. public investment fund as well as HBM Partners, Hillhouse Capital, Sirona Capital and the strategic investor Gilead. The existing investors of Hookipa, namely Sofinnova Partners, Forbion Capital Partners, Boehringer Ingelheim Venture Fund, Takeda Ventures and BioMedPartners, also participated in the financing. An infection with CMV is harmless for healthy people, but can be deadly for people with weakened immune systems, especially following organ transplants. An infection during pregnancy can also have fatal consequences for the baby.Founded in 2011, the company develops active immunotherapies against cancer and infectious diseases. The new investors include a blue-chip U.S. public investment fund as well as HBM Partners, Hillhouse Capital, Sirona Capital and the strategic investor Gilead. The existing investors of Hookipa, namely Sofinnova Partners, Forbion Capital Partners, Boehringer Ingelheim Venture Fund, Takeda Ventures and BioMedPartners, also participated in the financing. An infection with CMV is harmless for healthy people, but can be deadly for people with weakened immune systems, especially following organ transplants. An infection during pregnancy can also have fatal consequences for the baby.

Share on Facebook Share on Facebook Share on Twitter Share on Twitter Share on Linkedin Share on Linkedin

Testimonials

Events

Meet us at events, seminars and trade shows - worldwide.

  • Business Location Austria

    24.09.2019, Bucharest, Romania

  • Business Location Austria

    25.09.2019, Cluj-Napoca, Romania

Austria Map

Find the perfect location for your company

Thanks to a fantastic mindset, our employees at the Villach site have built up a unique expertise which helps us to further strengthen our position on the global market. We fuse high-performance manufacturing with research and development in the field of power electronics. In addition to a very good cooperation with partners and networks, a well-developed landscape of 'talent factories' ranging from higher technical colleges to universities, we as a company also value the outstanding model of research promotion which exists in Austria.

Infineon

Logo Infineon
More testimonials

news from the business location Austria

ERC Starting Grant for molecular biologist in Innsbruck

The molecular biologist Jerome Mertens received a Starting Grant of the European Research Council (ERC) for his research into understanding the molecular and cellular causes of aging, especially brain aging and molecular cell biology of Alzheimer's disease in nerve cells.

Not Only for Startups: The Business Plan as the Road Map to Success

A great idea has been born. The product the world is waiting for has been invented. Actually, nothing can seemingly go wrong. At least one would be inclined to think so. However, the best idea or invention is worthless without a business plan to successfully bring the idea down to earth. Here you will find out what you should take into consideration when drawing up a business plan.

More news All blog posts